

ASX Release

**Oventus 2018 Annual General Meeting
dial in details**

Brisbane, Australia 15th November 2018: Oventus Medical Ltd (ASX: OVN), is pleased to invite shareholders to participate in the 2018 Annual General Meeting (AGM) via a dial-in facility, to be held in Brisbane tomorrow, on 16th November from 11:30 am AEST (Brisbane time.)

The meeting will be chaired by Chairman, Dr Mel Bridges, and will include a presentation from CEO, Dr Chris Hart and Vice President, Marketing and Operations, Robin Randolph.

The AGM presentation will be lodged on the morning of the AGM, along with a copy of the Chairman's script.

Date and time of meeting / conference call

Friday, 16th November 2018 from 11:30 am Brisbane time (AEST.)

Dial in details

Australian toll free:	1800 123 296
Australian local (Sydney):	+61 2 8038 5221
New Zealand:	0800 452 782
United Kingdom:	0808 234 0757
United States:	1855 293 1544

Conference ID

7466219

Shareholders attending in person

Please attend McCullough Robertson, Level 11, 66 Eagle Street, Brisbane QLD 4000 for an 11:30 am start.

For further information, please visit our website at www.ventus.com.au or contact the individuals outlined below.

--ENDS--

For more information, please contact:

Dr Chris Hart, Managing Director and CEO: M: +61 409 647 496

Jane Lowe, IR Department: M: +61411 117 774 or jane.lowe@irdepartment.com.au

About Oventus

Oventus is a Brisbane based medical device company that is commercialising a unique treatment platform for the treatment of sleep apnoea and snoring. Unlike other oral appliances or CPAP interfaces, the Oventus devices have a unique and patented airway within the treatment platform that allows air to flow to the back of the mouth unobstructed while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue, reducing airway collapsibility and managing mouth breathing while maintain a stable airway with or without nasal CPAP. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, this technology actually manages mouth breathing by converting it to device breathing and normalising ventilation. The O₂Vent™ is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.¹

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, however many patients have difficulty tolerating CPAP². Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.³

¹ Deloitte Access Economics. *Reawakening Australia: the economic cost of sleep disorders in Australia, 2010*. Canberra, Australia.

² Beecroft, et al. Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. *Chest* 124:2200–2208, 2003

³ Sutherland et al. Oral appliance treatment for obstructive sleep apnea: An updated *Journal of Clinical Sleep Medicine*. February 2014.